ABCL vs KMB · rev $12.4M vs P/E 19, rev $8.35B
Abcellera Biologics Inc (ABCL) versus Kimberly-Clark Corporation (KMB) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
Latest reported KMB revenue for 2026-06-30 was $8.35B. Net income was $1.01B. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
ABCL currently screens at market cap $1.12B. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Not investment advice. Open the ABCL and KMB stock pages for the full models.
Not investment advice.